Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Tomasz Romer"'
Autor:
Marta Rydzewska, Tomasz Romer, Adrianna Zajkowska, Janusz Pomaski, Artur Bossowski, Katarzyna Wojtkielewicz
Publikováno v:
Pediatric endocrinology, diabetes, and metabolism. 23(1)
Inactivating mutations in the enzyme hexose-6-phosphate dehydrogenase (H6PDH), the enzyme responsible for NADPH generation playing critical role in 11-hydroxysteroid dehydrogenase type 1 (11b-HSD1) activity, cause apparent cortisone reductase deficie
Autor:
Maria Victoria Borrás Pérez, Nadja Höbel, Markus Zabransky, Tomasz Romer, Mieczysław Walczak, Berit Kriström
Publikováno v:
Drug Design, Development and Therapy
Safety concerns for recombinant human growth hormone (rhGH) treatments include impact on cancer risk, impact on glucose homeostasis, and the formation of antibodies to endogenous/exogenous GH. Omnitrope (R) (biosimilar rhGH) was approved by the Europ
Autor:
A. Berghout, Nora Saraco, Stefano Cianfarani, Filiz Tutunculer, Selda Can Arkaya, Carolina Pepe, Firdevs Bas, Ioannis Papassotiriou, Arianna Maiorana, Mariana Prieto, Semra Abbasoglu, Tomasz Romer, Carmen Mazza, Maria Dracopoulou, G. Nick Angelopoulos, Catherine Dacou-Voutetakis, Carolina M. Pepe, Sarantis Livadas, Juliana de Vasconcellos Thomas, Gabriela Guercio, M A Rivarola, George P. Chrousos, Ferenc Péter, Y. Le Bouc, Alessandra Fierabracci, A. Belgorosky, Paulo Ferrez Collett-Solberg, Mieczysław Walczak, J. Khan-Boluki, Alicia Belgorosky, Carola Saure, Nurçin Saka, Marco A. Rivarola, Christina Lazaropoulou, N. Saraco, Paul Saenger, Maria Isabel Di Palma, Amalia Sertedaki
Publikováno v:
Hormone Research in Paediatrics. 72:I-IV
Autor:
Mieczysław Walczak, J. Khan-Boluki, Tomasz Romer, A. Berghout, Paul Saenger, Y. Le Bouc, Ferenc Péter
Publikováno v:
Hormone Research in Paediatrics. 72:359-369
Aim: This phase III clinical study in growth hormone deficiency (GHD) children with growth retardation was designed to compare efficacy and safety of Omnitrope® with Genotropin® and assess the long-term safety and efficacy of Omnitrope®. The resul
Autor:
Paul Saenger, Valentina Alexandrovna Peterkova, Hyi-Jeong Ji, Ilknur Arslanoglu, Elena Bolshova-Zubkovskaya, Tomasz Romer, Jürgen Kratzsch, Conrad Savoy, Dragan Zdravkovic
Publikováno v:
Hormone Research in Paediatrics. 68:288-293
Valtropin is a recombinant human GH (rhGH) manufactured using a novel yeast expression system, classed as a ‘biosimilar’. Valtropin was compared with Humatrope in children with GH deficiency (GHD). Treatment-naive, prepubertal children with GHD w
Publikováno v:
Hormone Research in Paediatrics. 59:205-210
Objective: We present the 1st case of prepubertal hyperandrogenism because of a defect in the conversion of cortisone (E) to cortisol (F) by hepatic11β-hydroxysteroid dehydrogenase type 1. Methods and Results: Clinical and anthropometric data were o
Autor:
Johannes D. Veldhuis, Valentina Alexandrovna Peterkova, Paul Saenger, Marta Barontini, Ilknur Arslanoglu, Martijn H. Breuning, María Cecilia García Rudaz, W. Oostdijk, Delphine Mitanchez, Tomasz Romer, Pierre Chatelain, Marwa E. Fahmi, Hyi-Jeong Ji, Peter J Simm, Robert L. Rosenfield, María Gabriela Ropelato, Pinchas Cohen, Conrad Savoy, Guy Van Vliet, María Gabriela Ballerini, M.H. de Ru, Mirta Gryngarten, Jürgen Kratzsch, G Bona, Mohamed El Kholy, Eileen Fowler, Samia Selim, Margaret Zacharin, Wolfgang G. Sippell, Melanie Shim, J.M. Wit, Heba Elsedfy, Elena Bolshova-Zubkovskaya, William L. Oppenheim, A. Ferrandez-Longas, Ayman E. Nassar, A. Carrascosa, Claude J. Migeon, M E Escobar, F K Grote, H.M. Zonderland, Dragan Zdravkovic, Omar Ali, S.G. Kant
Publikováno v:
Hormone Research in Paediatrics. 68:327-329
Publikováno v:
European Journal of Pediatrics. 157:539-543
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency suspected in 14 newborns (5 F, 9 M), was treated prenatally with dexamethasone from weeks 7-9 of gestation. The 24 h urinary excretion of selected adrenocortical steroids derived from fe
Autor:
A. Fabbo, G. Schreiber, Zvi Zadik, Giorgio Valenti, Christian J. Strasburger, Z. Iwanicka, Guy Massa, Z. Mitkowska, Juergen Kratzsch, Cees Noordam, K. Bal, B.J. Otten, Erik Schoute, M. Freddi, N. Reali, E. Moszczyńska, T. Selisko, Joost Rotteveel, Marije Hogeveen, G. Troglio, Tomasz Romer, Eberhard Keller, M. Maggio, Ewa M. Małunowicz, T. Niżankowska-Błaż, Henrieite A. Delemarre-van de Waal, Graziano Ceresini, C.D. Pflaum, Christine M. De Ridder, Jan M. Wit, Amnon Zung
Publikováno v:
Hormone Research. 48:I-IV
Publikováno v:
Biologics in Therapy
Introduction Recombinant human growth hormone (rhGH) is effective and safe when used to treat growth hormone deficiency (GHD) in children. However, it has been suggested that switching between different types of rhGH can have a detrimental effect on